Skip to main content
Premium Trial:

Request an Annual Quote

AGT Biosciences and ChemGenex Merge

NEW YORK, April 28 (GenomeWeb News) - AGT Biosciences of Melbourne, Australia, and ChemGenex Therapeutics of Menlo Park, Calif., yesterday announced a merger agreement.


AGT Biosciences, which lists Merck-Sante as a major shareholder, will issue 28 million shares of common stock to acquire all of the issued shares of privately held ChemGenex. Further financial details were not disclosed.


The combined entity will do business as ChemGenex Pharmaceuticals with Dennis Brown, CEO of ChemGenex,  serving as president of the combined firm. Brown co-founded Matrix Pharmaceutical, which was acquired by Chiron in 2002.


ChemGenex will maintain its Center for Statistical Genomics in San Antonio, Texas, the company said.


The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.